Diabetic Nephropathy - Drug Pipeline Landscape, 2023

Diabetic Nephropathy - Drug Pipeline Landscape, 2023

Diabetic Nephropathy (DN) also called as diabetic kidney disease (DKD) is a long-term kidney damage or disease that can affect people with diabetes. Diabetic Nephropathy affects the ability of kidney to remove wastes and extra fluid from the body.

The most common cause of Diabetic Nephropathy is Type 1 and Type 2 Diabetes which increase the blood pressure. Any damage caused to blood vessels results in high blood pressure which will increase the pressure in the filtering system of the kidneys, which can cause severe damage lead to decreased kidney function and eventually kidney failure.

Symptoms include swollen ankles, feet, lower legs, or hands due to water retention, frequent urination, high blood pressure, darker urine due to traces of blood, shortness of breath, fatigue due to lack of oxygen in the blood, nausea, vomiting, poor appetite, metallic taste in the mouth, abnormal heart rhythm due to high potassium in blood.

Doctors most often diagnose Diabetic Nephropathy by blood and urine tests, imaging tests, Renal function tests, Kidney biopsy.

The most common treatments for Diabetic Nephropathy are medications which will control the blood pressure, blood sugar, cholesterol level, and protein in the urine for the early stage and dialysis or Kidney transplant for advanced stage.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Nephropathy treatment such as SER150, CS-3150, BI 685509, Bardoxolone Methyl and others. Key players involved in the development of therapies to treat diabetic nephropathy are Serodus ASA, Daiichi Sankyo Co Ltd, Kyowa Kirin Co Ltd, Novartis, Boehringer Ingelheim and others. Four drugs are under late-stage Phase III clinical trials, nineteen drugs are in Phase II clinical trials, seven drugs are in Phase I clinical trials and some other drugs are under IND/CTA Filed, Preclinical and Discovery stages of development.

In October 2022, Serodus ASA decided to change to an Australian based CRO working after international GCP guidelines and Australian ethical committee has approved increasing dosing period from 3 to 6 months. Serodus ASA announced that European Patent office has Published a SER150 patent which prolongs the patent protection until 2040.

Report Highlights

Global Insight Service's, Diabetic Nephropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Nephropathy pipeline drugs. This report covers detailed insights on Diabetic Nephropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Nephropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.